Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385213 | 0.90 | HPGD (0.76) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL7105506 | 0.85 | HPGD (0.65) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL5884635 | 0.83 | HPGD (0.67) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL21123536 | 0.82 | HPGD (0.61) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL24227389 | 0.81 | RAB9A (0.69) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL13397394 | 0.81 | HPGD (0.65) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL17426924 | 0.81 | HPGD (0.65) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL9068167 | 0.81 | PKM (0.68) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL28804019 | 0.81 | SMN1; SMN2 (0.69) | LMNAHPGDALDH1A1SMN1; SMN2PKM | |
| SCHEMBL17426921 | 0.81 | HPGD (0.65) | LMNAHPGDALDH1A1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343303-A1 | PI3-kinase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-7638546-B1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070299073-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2007-12-27 | — | — | US | disclosed |
| US-7238695-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-5859299-A | Process for making nitro and amino substituted benzamides | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-4841036-A | COLORFAST, HEAT RESISTANCE | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1989-06-20 | — | — | US | disclosed |
| US-4837309-A | IMPROVED COLORFASTNESS AND LIGHTFASTNESS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0108570-B1 | DISAZO DYESTUFFS FOR CELLULOSE-CONTAINING FIBRES AND PROCESS FOR PREPARING THE DYESTUFF | MITSUBISHI KASEI CORPORATION (JP) | 1986-10-29 | — | — | EP | disclosed |
| EP-0121825-B1 | MONOAZO DYESTUFFS FOR CELLULOSE-CONTAINING FIBERS | MITSUBISHI KASEI CORPORATION (JP) | 1986-09-10 | — | — | EP | disclosed |
| US-4118503-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-4117138-A | ANTIULCER | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4064264-A | Pyrrolidonecarboxylic acid derivatives as anti-ulcer agents | PFIZER INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4044147-A | N-(acyl)-p-amino-N'-(monosubstituted)-benzamide anti-ulcer agents | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299073-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | LMNA 4751/4885HPGD 2463/4885ALDH1A1 2490/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | LMNA 4166/4885HPGD 3537/4885ALDH1A1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.